(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
20 August 2020 (20.08.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/168122 A1

(51) International Patent Classification:
C12N 9/22 (2006.01) *C12Q 1/00* (2006.01)
C12N 9/78 (2006.01) *C12Q 1/34* (2006.01)
C12N 15/113 (2010.01) *C12Q 1/68* (2018.01)
C12N 15/55 (2006.01)

(21) International Application Number:
PCT/US2020/018178

(22) International Filing Date:
13 February 2020 (13.02.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/805,271	13 February 2019 (13.02.2019)	US
62/852,228	23 May 2019 (23.05.2019)	US
62/852,224	23 May 2019 (23.05.2019)	US
62/931,722	06 November 2019 (06.11.2019)	US
62/941,569	27 November 2019 (27.11.2019)	US
62/941,523	27 November 2019 (27.11.2019)	US
62/966,526	27 January 2020 (27.01.2020)	US

(71) Applicant: **BEAM THERAPEUTICS INC.** [US/US]; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **GAUDELLI, Nicole**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **PACKER, Michael**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **SLAYMAKER, Ian**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **YU, Yi**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **ZETSCHE, Bernd**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **BORN, David A.**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **LEE, Seung-Joo**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US). **GEHRKE, Jason M.**; 26 Landsdowne Street, 2nd Floor, Cambridge, Massachusetts 02139 (US).

(74) Agent: **HUNTER-ENSOR, Melissa**; Greenberg Traurig, LLP, One International Place, Suite 2000, Boston, MA 02110 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: MODIFIED IMMUNE CELLS HAVING ADENOSINE DEAMINASE BASE EDITORS FOR MODIFYING A NUCLEOBASE IN A TARGET SEQUENCE

(57) Abstract: The present invention features genetically modified immune cells comprising novel adenosine base editors (*e.g.*, ABE8) having enhanced anti-neoplasia activity, resistance to immune suppression, and decreased risk of eliciting a graft-versus-host reaction or host-versus-graft reaction, or a combination thereof. The present invention also features methods for producing and using these modified immune effector cells.




FIG. 1A

WO 2020/168122 A1

[Continued on next page]

SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*